Related Experiment Video
Updated: Jul 9, 2025

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers
Published on: September 20, 2018
Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer
Laura Helminen1, Jasmin Huttunen1, Melina Tulonen1
1Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
Abstract:
Treatment of prostate cancer relies predominantly on the inhibition of androgen receptor (AR) signaling. Despite the initial effectiveness of the antiandrogen therapies, the cancer often develops resistance to the AR blockade. One mechanism of the resistance is glucocorticoid receptor (GR)-mediated replacement of AR function. Nevertheless, the mechanistic ways and means how the GR-mediated antiandrogen resistance occurs have remained elusive. Here, we have discovered several crucial features of GR action in prostate cancer cells through genome-wide techniques. We detected that the replacement of AR by GR in enzalutamide-exposed prostate cancer cells occurs almost exclusively at pre-accessible chromatin sites displaying FOXA1 occupancy. Counterintuitively to the classical pioneer factor model, silencing of FOXA1 potentiated the chromatin binding and transcriptional activity of GR. This was attributed to FOXA1-mediated repression of the NR3C1 (gene encoding GR) expression via the corepressor TLE3. Moreover, the small-molecule inhibition of coactivator p300's enzymatic activity efficiently restricted GR-mediated gene regulation and cell proliferation. Overall, we identified chromatin pre-accessibility and FOXA1-mediated repression as important regulators of GR action in prostate cancer, pointing out new avenues to oppose steroid receptor-mediated antiandrogen resistance.
Insights
Glucocorticoid receptor (GR) can replace androgen receptor (AR) in prostate cancer, driving resistance to antiandrogen therapies. We found FOXA1 represses GR, and inhibiting p300 blocks GR activity, offering new therapeutic strategies.
Area of Science:
- Molecular Biology
- Oncology
- Genomics
Background:
- Prostate cancer treatment often involves androgen receptor (AR) signaling inhibition.
- Cancer cells can develop resistance to antiandrogen therapies.
- Glucocorticoid receptor (GR) can mediate resistance by replacing AR function, but mechanisms are unclear.
Purpose of the Study:
- To elucidate the mechanisms of GR-mediated antiandrogen resistance in prostate cancer.
- To identify key regulators of GR action in this context.
Main Methods:
- Genome-wide techniques were employed to study GR action in prostate cancer cells.
- Analysis of chromatin accessibility and transcription factor occupancy (FOXA1).
- Gene silencing (FOXA1) and small-molecule inhibition (p300 coactivator).
Main Results:
- GR replaces AR at pre-accessible chromatin sites marked by FOXA1 in resistant cells.
- FOXA1 silencing enhanced GR chromatin binding and activity.
- FOXA1 represses NR3C1 (GR gene) expression via TLE3 corepressor.
- Inhibiting p300's enzymatic activity blocked GR-mediated gene regulation and proliferation.
Conclusions:
- Chromatin pre-accessibility and FOXA1-mediated repression are critical regulators of GR action in prostate cancer.
- These findings reveal novel strategies to overcome steroid receptor-mediated antiandrogen resistance.
More Related Videos
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
09:07Prediction and Validation of Gene Regulatory Elements Activated During Retinoic Acid Induced Embryonic Stem Cell Differentiation
Published on: June 21, 2016
Related Concept Videos
Co-activators and Co-repressors
Master Transcription Regulators
Epigenetic Regulation
X-chromosome...
RNA Polymerase II Accessory Proteins
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
Cell Specific Gene Expression